Table 1. Commercially available antiviral agents tested, source and starting concentration.
| Antiviral agent | Source | Highest concentration tested | Inhibition of cytopathic effect (CIA100) |
|---|---|---|---|
|
Interferons
| |||
| Interferon α-2a (Roferon) |
Roche |
100,000 IU/mL |
No |
| Interferon α-2b (Intron A) |
Schering-Plough |
500,000 IU/mL |
No |
| Interferon α-n1 (Wellferon) |
GlaxoSmithKline |
500,000 IU/mL |
Yes |
| Interferon α-n3 (Alferon) |
Hemispheryx |
10,000 IU/mL |
Yes |
| Interferon β-1a (Rebif) |
Serono |
500,000 IU/mL |
No |
| Interferon β-1b (Betaferon) |
Schering AG |
100,000 IU/mL |
Yes |
|
Nucleoside analogs
| |||
| Acyclovir |
Faulding |
1,000 μg/ml |
No |
| Cymevene (Ganciclovir) |
Roche |
50,000 μg/mL |
No |
| Ribavirin |
ICN Pharma |
10,000 μg/mL |
Yes |
|
Protease inhibitors
| |||
| Indinavir (Crixivan) |
Merck |
100 μM |
No |
| Nelfinavir (Viracept) |
Roche |
10,000 nM |
No |
| Saquinavir (Fortovase) |
Roche |
10,000 nM |
No |
|
Reverse transcriptase inhibitors
| |||
| Lamivudine (Epivir) |
GlaxoSmithKline |
1,000 μM |
No |
| Zidovudine (Retrovir) |
GlaxoSmithKline |
1,000 μg/mL |
No |
|
Neuraminidase inhibitors
| |||
| Oseltamivir (Tamiflu) |
Roche |
10,000 μM |
No |
| Zanamivir (Relenza) |
GlaxoSmithKline |
1,000 μM |
No |
|
Other
| |||
| Amantadine (Symmetrel) |
Novartis |
1,000 μg/mL |
No |
| Foscarnet (Foscavir) | AstraZeneca | 8,000 μM | No |